10-Q - ABVC BIOPHARMA, INC. (0001173313) (Filer)

Wed, Apr 30, 8:47 PM (11 days ago)

### Summary of ABVC BioPharma, Inc. (ABVC) Q1 2025 Financial Performance **Ticker:** ABVC **Quarterly Financial Health:** - **Revenue:** $0 (flat from Q1 2024) - **Profit Margins:** Not applicable due to negative net income. - **Cash Flow:** Negative cash flow from operations of $539,833. - **Earnings Changes:** Net loss of $944,190, a decrease of 68% from Q1 2024. **Quarterly Performance Discussion:** - **Revenue:** No revenue was generated in Q1 2025, similar to Q1 2024. - **Operating Expenses:** Decreased by $2,146,178 (76%) to $693,005, primarily due to reductions in selling, general, and administrative expenses, and research and development expenses. - **Interest Income/Expense:** Net interest expense increased by $26,269 (15%) to $203,896, mainly due to the recognition of interest expense for converted notes. - **Other Expenses:** Increased by $161,773 (181%) to $251,185, primarily due to loss on equity investment and interest expense, offset by a decrease in gain on foreign exchange changes. - **Net Loss:** Decreased by $1,983,477 (68%) to $944,190. **Trends and Uncertainties:** - **Liquidity Risks:** The company reported a working capital deficit of $5,261,178 and net cash outflows of $539,833 from operating activities, raising substantial doubt about its ability to continue as a going concern. - **Future Operations Impact:** The company plans to improve operations, generate positive cash flows, and raise additional capital through private or public offerings to address liquidity needs. **Future Outlook:** - **Strategic Initiatives:** The company aims to advance its pipeline, focus on licensing agreements, and complete clinical trials to generate future revenues. - **Financial Strategy:** The company will continue to control operating expenses, reduce debts, and explore additional financing options to sustain operations and growth.